Improving outcomes for people with skin tumours including melanoma

More documents

Recommendations

Info

Improving Outcomes for People with Skin Tumours including Melanoma Management of special groups Observational studies that address the risk of melanoma arising from congenital melanocytic naevi (CMN) report that children with large CMN are at greatly increased risk of cutaneous and non-cutaneous melanoma, warranting continuous surveillance. Larger CMN pose a greater risk than smaller lesions. Small CMN (< 10 cm in largest diameter) are considered precursors to epidermal melanoma which largely occurs after puberty. Giant nevi (> 20 cm in largest diameter) pose a risk for dermal melanoma predominantly in pre-pubescent children, although these naevi may also produce epidermal melanomas after puberty. Lymphoma Clinical guidelines and expert reviews support the opinion that patients with cutaneous lymphoma should be managed by an MDT. One RCT demonstrated that early intervention in mycosis fungoides using multi-agent chemotherapy does not improve survival but does increase morbidity. 6 Clinical guideline evidence supports avoidance of toxic or aggressive therapies in the treatment of patients with early-stage disease. Skindirected treatment (topical therapy, superficial radiotherapy and phototherapy) has been shown to achieve long periods of remission and is the most appropriate therapy in early-stage disease. Five-year survival varies according to lymphoma type and is estimated to be 70–90% in patients with mycosis fungoides and 10–50% in patients with Sézary syndrome. The quality of life of patients with cutaneous lymphoma may be severely affected over many years. Kaposi’s sarcoma Two expert reviews found that HAART is associated with a dramatic decrease in the incidence of KS and can bring about tumour regression. One observational study found that HAART is associated with prolonged disease control in patients with KS. Expert review evidence reports that local therapies including cryotherapy, radiotherapy and topical treatments are effective for treating patients with early skin lesions and that, in general, systemic chemotherapy for KS is a treatment option for patients with widespread, symptomatic disease. 122 National Institute for Health and Clinical Excellence
Gorlin’s syndrome Two expert reviews report that people with Gorlin’s syndrome have an increased risk of developing BCCs, with onset as early as 2 years but usually from puberty to 35 years of age. This risk increases with exposure to sunlight. Patients with the syndrome may develop thousands of BCCs, ranging in size from 1 mm to 10 mm in diameter and most often involving the face, back and chest. Topical body application of tretinoin or fluorouracil can control lesions. The use of oral retinoids is debated. PDT can give a high rate of tumour response. There is evidence that radiotherapy should not be used in patients with Gorlin’s syndrome. Improving Outcomes for People with Skin Tumours including Melanoma Management of special groups Transplant patients One RCT comparing two doses of oral acitretin in renal transplant recipients found that oral acitretin reduces the number of actinic keratoses, although the drug was poorly tolerated by patients. Evidence-based guidelines produced by the Evidence Based Practice Group, Expert Group on Renal Transplantation (2002) recommend that patients should be educated about primary prevention of skin cancer and that transplant recipients with pre-malignant skin lesions should be referred early to a dermatologist. Secondary prevention for recipients should include close follow-up by a dermatologist and treatments for skin cancer including topical retinoids, reduction of immunosuppression whenever possible and, for multiple or recurrent skin cancer, systemic retinoids. 6 Evidence from observational and expert review studies suggests that transplant patients are at increased risk of developing skin cancer. SCC is the most common post-transplantation skin cancer, occurring earlier and growing more quickly than in the general population. The risk appears to be greater where immunosuppression is intense or maintained for a long time. Observational and clinical guideline evidence suggests that chemoprophylaxis with systemic retinoids may reduce the incidence of skin cancer. Observational study evidence suggests that reducing or stopping immunotherapy can be an option for managing skin cancer only after careful consideration of the risk of organ rejection with the patient’s transplant physician. A survey of transplant physicians reported that closely integrated and well-coordinated specialist clinics for dermatological management of transplant patients are highly effective. Guidance on cancer services: skin tumours including melanoma 123
Page 1 and 2:
NHS National Institute for Health a
Page 3 and 4:
Contents Improving Outcomes for Peo
Page 5 and 6:
Patient information ...............
Page 7 and 8:
Resource implications .............
Page 9 and 10:
Foreword Improving Outcomes for Peo
Page 11 and 12:
- referral - review of patient care
Page 13 and 14:
early detection have been published
Page 15 and 16:
The epidemiology of skin cancers an
Page 17 and 18:
The incidence of MM increases with
Page 19 and 20:
Figure 5. Mortality from MM, Englan
Page 21 and 22:
Figure 8. Incidence of NMSC, Englan
Page 23 and 24:
Risk factors for skin cancer As ski
Page 25 and 26:
Figure 12. Rates of episodes of inp
Page 27 and 28:
Two-week wait data Urgent skin canc
Page 29 and 30:
• Improving the experience of car
Page 31 and 32:
12. National Institute for Clinical
Page 33 and 34:
Patient-centred care Improving Outc
Page 35 and 36:
This document and the NICE Referral
Page 37 and 38:
A checklist may be used by healthca
Page 39 and 40:
Quality assurance Surveys of patien
Page 41 and 42:
One cross-sectional study found tha
Page 43 and 44:
One RCT conducted with patients wit
Page 45 and 46:
• Every skin cancer MDT having ac
Page 47 and 48:
to estimate a separate cost for ser
Page 49 and 50:
department or they may be referred
Page 51 and 52:
The 2-week waiting time standard an
Page 53 and 54:
The local hospital skin cancer mult
Page 55 and 56:
A function of the LSMDT is to audit
Page 57 and 58:
• lymphoedema therapists • phar
Page 59 and 60:
SSMDT meetings should be at least f
Page 61 and 62:
As set out in the section on ‘Arr
Page 63 and 64:
• Palliative care specialists. Si
Page 65 and 66:
Videoconferencing and teleconferenc
Page 67 and 68:
A basic knowledge of skin cancer hi
Page 69 and 70:
B. Anticipated benefits At present,
Page 71 and 72:
One systematic review (of the abili
Page 73 and 74: One retrospective study compared pa
Page 75 and 76: • Critical incidents where treatm
Page 77 and 78: Network-wide protocols It is not po
Page 79 and 80: Initial investigation, diagnosis, s
Page 81 and 82: Figure 14. Skin lesion - patient pa
Page 83 and 84: curettage (as recommended in BAD gu
Page 85 and 86: Diclofenac 3% gel (Solaraze) is lic
Page 87 and 88: Histopathology services for skin ca
Page 89 and 90: Patients with anogenital Bowen’s
Page 91 and 92: B. Anticipated benefits Better-qual
Page 93 and 94: One RCT compared teledermatology wi
Page 95 and 96: One systematic review based upon 12
Page 97 and 98: Expert review evidence suggests tha
Page 99 and 100: Immunotherapy An RCT comparing allo
Page 101 and 102: • Adherence to treatment protocol
Page 103 and 104: F. Research priorities • Given th
Page 105 and 106: For patients with low-risk BCC or S
Page 107 and 108: Follow-up for patients after treatm
Page 109 and 110: C. Evidence Evidence exists that ea
Page 111 and 112: One observational study found that
Page 113 and 114: The written and photographic inform
Page 115 and 116: Genetic predisposition to MM may al
Page 117 and 118: patients with cutaneous lymphoma sh
Page 119 and 120: A. Recommendations Generic recommen
Page 121 and 122: Cutaneous lymphoma All patients sho
Page 123: Children and young people with skin
Page 127 and 128: Process • Audit of adherence to p
Page 129 and 130: • Cutaneous lymphoma is so rare t
Page 131 and 132: Dermal and subcutaneous tumours Aty
Page 133 and 134: c) The guidance will also refer to
Page 135 and 136: 4.2.2 Healthcare settings and servi
Page 137 and 138: Referral from the Department of Hea
Page 139 and 140: Table A1. Summary of service option
Page 141 and 142: For those cancer networks with part
Page 143 and 144: Appendix 4 How this guidance manual
Page 145 and 146: Appendix 5 People and organisations
Page 147 and 148: Professor Julia Newton-Bishop Mr Ba
Page 149 and 150: • Bristol South and West PCT •
Page 151 and 152: • Healthcare Commission • Help
Page 153 and 154: • Royal College of Surgeons of En
Page 155 and 156: Appendix 5.3 Researchers carrying o
Page 157 and 158: Appendix 5.4 Expert advisers to the
Page 159 and 160: Appendix 5.5 Report* commissioned t
Page 161 and 162: Appendix 6 Glossary of terms Improv
Page 163 and 164: Chemoprophylaxis The use of a drug
Page 165 and 166: Electrodesiccation A surgical metho
Page 167 and 168: Immunotherapy Treatment by stimulat
Page 169 and 170: Morbidity A diseased condition or s
Page 171 and 172: Prognosis A prediction of the likel
Page 173 and 174: Systemic therapy Treatment that rea
Page 175 and 176:
KS LHB LSMDT MCC MDT MM MRI NCC-C N
show all

Improving outcomes for people with skin tumours including melanoma

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?